Immunoconjugates

Known as: Icon, Immunoconjugate, Immunoconjugates [Chemical/Ingredient] 
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or… (More)
National Institutes of Health

Related topics

Related topics

39 relations

Narrower (29)

AGS67EAMG 595ANG4043D2C7-(scdsFv)-PE38KDEL
(More)

Broader (2)

AntibodiesImmunologic Factors
BRENTUXIMABBispecific CD19-directed CD3-directed T Cell Engager [EPC]ImmunotherapyImmunotoxicity
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per… (More)
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Contribution of linker stability to the activities of anticancer immunoconjugates.
The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are… (More)
Is this relevant?
Review
2005
Review
2005
Arming antibodies: prospects and challenges for immunoconjugates
Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.
Immunoconjugates are being explored as novel cancer therapies with the promise of target-specific drug delivery. The… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 6
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer…
The anticancer drug doxorubicin (DOX) has been linked to chimeric BR96, an internalizing monoclonal antibody that binds to a… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
Antibody-targeted chemotherapy is a promising therapy in patients with acute myeloid leukemia (AML). In a phase II study of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Leukemic blast cells express the CD33 antigen in most patients with acute myeloid leukemia (AML), but this antigen is not… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
The potential of immunoconjugates of cytotoxic drugs for the treatment of cancer has not yet been realized owing to the… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?